Breckenridge Pharmaceutical, Inc. recalls
12 notices naming Breckenridge Pharmaceutical, Inc. as the recalling firm, since January 1, 2025. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules USP
Hazard (FDA): CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
FDAMedicines
Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules USP and 1 more
Hazard (FDA): CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules
Hazard (FDA): CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc.: Duloxetine Delayed-Release Capsules and 2 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines
Breckenridge Pharmaceutical, Inc: Duloxetine Delayed-Release Capsules and 1 more
Hazard (FDA): CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
FDAMedicines